SAB Biotherapeutics (SABS) Stock Price, News & Analysis

Company Overview

SAB Biotherapeutics, Inc. is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases. SAB-185, its anti-SARS-CoV-2 polyclonal antibody candidate, advanced through clinical trials for the treatment and prevention of COVID-19. In addition to its coronavirus program, SAB Biotherapeutics is exploring pipeline candidates against other emerging pathogens, including Zika virus, MERS, and chikungunya virus. Beyond infectious disease, the Tc Bovine® platform has potential applications in oncology and chronic inflammatory conditions, where diverse antibody repertoires may address antigenic variation and tumor heterogeneity.

Since its founding in 2008, SAB Biotherapeutics has pursued strategic collaborations with government agencies, academic institutions, and industry partners to accelerate development of its antibody therapeutics. The company operates its biomanufacturing and research facilities in Sioux Falls and maintains collaborations across the United States for preclinical and clinical studies. By leveraging its transchromosomic cattle system, SAB Biotherapeutics aims to provide a rapid response capability for emerging public-health threats, while building a diversified pipeline of immune-based therapies for multiple indications.

Key Stats

• Today's Range: $3.78 to $4.13
• 50-Day Range: $3.47 to $4.59
• 52-Week Range: $1.60 to $6.60
• Volume: 712,743 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $198.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

SAB Biotherapeutics Stock Analysis - MarketRank™

SAB Biotherapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 259th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

SAB Biotherapeutics has a consensus price target of $11.00, representing about 182.8% upside from its current price of $3.89.

Amount of Analyst Coverage

SAB Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($1.10) to ($0.44) per share.

Price to Book Value per Share Ratio

SAB Biotherapeutics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.33% of the float of SAB Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

SAB Biotherapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in SAB Biotherapeutics has recently decreased by 19.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SAB Biotherapeutics does not currently pay a dividend.

Dividend Growth

SAB Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.27

News Sentiment

SAB Biotherapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for SAB Biotherapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SABS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.06% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.82% of the stock of SAB Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SABS
• CIK: 1833214
• Web: www.bigcypressaccorp.com
• Phone: 605-679-6980
• Fax: N/A
• Employees: 140
• Year Founded: 2014

Price Target and Rating

• Average Price Target for SAB Biotherapeutics: $11.00
• High Price Target: $15.00
• Low Price Target: $7.00
• Potential Upside/Downside: +182.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $13.27 million
• Net Margins: N/A
• Pretax Margin: 16,294.78%
• Return on Equity: -0.29%
• Return on Assets: -0.25%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 11.45
• Quick Ratio: 9.46

Sales & Book Value

• Annual Sales: $1.32 million
• Price / Sales: 150.15
• Cash Flow: $0.34 per share
• Price / Cash Flow: 11.59
• Book Value: $4.46 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 50,950,000
• Free Float: 38,183,000
• Market Cap: $198.20 million
• Optionable: Not Optionable
• Beta: 0.55